Pharming Group
PHAR
Performance
About Pharming Group
Pharming Group is a global biopharmaceutical company focused on the development and commercialization of innovative medicines to serve unserved rare disease patients. It operates internationally, highlighting a portfolio of products and ongoing research aimed at addressing niche medical needs in the rare disease space. The company emphasizes patient-centric therapies and investor-focused updates, with headquarters connected to its European roots as reflected in its branding. Pharming is dedicated to advancing treatments for underserved patient populations through clinical development and strategic partnerships.
Recent News
Burnout Common but Regrets Are Not in Allergy, Immunology
One-Time Infusion Lowers Hereditary Angioedema Attack Rate
FDA Accepts Pharming's Joenja Resubmission, Paving Way for Pediatric APDS Treatment
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
Pharming Group Secures EU Approval for Joenja, First Treatment for Rare Immunodeficiency
EMA Marketing Authorization of New Drugs in May 2026
Pharming Reports the EC Approval of Joenja (Leniolisib) for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
FDA Knocks Back Pharming's Bid for Wider Joenja Use
Recent Deals
No recent deals for this company.